SCHEMBL14745744

SCHEMBL14745744

COC(=O)c1c(O)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1ccc(N(C)C)cc1CCC2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 7/20 0.39
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
TSHR P16473 2/20 0.36
EDNRB P24530 2/20 0.36
MAPT P10636 2/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 2/20 0.35
ATM Q13315 1/20 0.35
TLR9 Q9NR96 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.34
F2 P00734 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745965 0.98 EGLN1 (0.39) EGLN1ALDH1A1POLBSMN1; SMN2GABRG2
SCHEMBL14745886 0.93 EDNRB (0.41) EGLN1ALDH1A1POLBSMN1; SMN2TSHR
SCHEMBL14745574 0.91 EDNRB (0.41) EGLN1ALDH1A1TSHREDNRBMAPT
SCHEMBL14746276 0.89 EGLN1 (0.40) EGLN1ALDH1A1POLBTSHREDNRB
SCHEMBL14745862 0.87 EGLN1 (0.40) EGLN1ALDH1A1POLBTSHREDNRB
SCHEMBL14745792 0.85 GABRG2 (0.44) EGLN1ALDH1A1SMN1; SMN2GABRG2GABRB3
SCHEMBL14745682 0.83 GABRG2 (0.44) EGLN1ALDH1A1SMN1; SMN2GABRG2GABRB3
SCHEMBL14745374 0.81 TSHR (0.39) EGLN1ALDH1A1POLBSMN1; SMN2TSHR
SCHEMBL14746181 0.81 EGLN1 (0.37) EGLN1ALDH1A1POLBSMN1; SMN2TSHR
SCHEMBL17895953 0.80 HPGD (0.42) EGLN1ALDH1A1POLBTSHREDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EGLN1 712/4885ALDH1A1 3792/4885POLB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.